Research from the Centre for Vision & Vascular Science at Queen’s University, Northern Ireland has reported on the potential therapeutic value of using an erythropoietin (EPO)-derived peptide for treatment of diabetic retinopathy. Despite the established pro-angiogenic effects of EPO with its potential to accelerate proliferative retinopathy, the research group believes that their approach may be capable of isolating the beneficial effects of tissue repair and suppression of inflammation associated with EPO. As such, the research may hold significant promise for clinical use in the treatment of the sight-threatening disorder.